Sugi Predict

Sugi Predict / Compounds / SCHEMBL4483089

SCHEMBL4483089

SCHEMBL4483089

Cc1ccc(S(=O)(=O)Oc2cccc3c(S(=O)(=O)NCc4cccc([N+](=O)[O-])c4)cccc23)cc1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 3/20 0.65
▸ CYP1A2 P05177 2/20 0.65
▸ CYP3A4 P08684 2/20 0.65
▸ CYP19A1 P11511 5/20 0.51
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ ESR1 P03372 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ ESR2 Q92731 1/20 0.47
▸ FABP4 P15090 1/20 0.45
▸ MAPT P10636 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ GPR17 Q13304 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471198 0.90 CYP1A2 (0.50) CYP2C19CYP1A2CYP3A4CYP19A1MEN1
SCHEMBL4479415 0.86 L3MBTL1 (0.52) CYP2C19CYP1A2CYP3A4CYP19A1MEN1
SCHEMBL4482026 0.86 CA12 (0.56) CYP1A2CYP3A4CYP19A1MEN1KMT2A
SCHEMBL4483280 0.85 CYP19A1 (0.50) CYP2C19CYP1A2CYP3A4CYP19A1MEN1
SCHEMBL4489698 0.83 NSD2 (0.49) CYP2C19CYP1A2CYP3A4CYP19A1MEN1
SCHEMBL4487088 0.82 MEN1 (0.57) CYP2C19CYP1A2CYP3A4CYP19A1MEN1
SCHEMBL4483934 0.82 MEN1 (0.52) CYP1A2CYP3A4CYP19A1MEN1KMT2A
SCHEMBL4473385 0.80 MEN1 (0.50) CYP1A2CYP3A4CYP19A1MEN1KMT2A
SCHEMBL4472800 0.79 POLB (0.57) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL4477941 0.79 MEN1 (0.49) CYP1A2CYP3A4CYP19A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 — — US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 — — US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 — — US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 CYP2C19 4553/4885CYP1A2 2887/4885CYP3A4 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.